Type I interferon pathway in pediatric systemic lupus erythematosus.

IF 6.1 2区 医学 Q1 PEDIATRICS World Journal of Pediatrics Pub Date : 2024-07-01 Epub Date: 2024-06-25 DOI:10.1007/s12519-024-00811-4
Yu Zhou, Hong-Mei Song
{"title":"Type I interferon pathway in pediatric systemic lupus erythematosus.","authors":"Yu Zhou, Hong-Mei Song","doi":"10.1007/s12519-024-00811-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The role of type I interferon (IFN-I) signaling in systemic lupus erythematosus (SLE) has been well established. However, unanswered questions remain regarding the applicability of these findings to pediatric-onset SLE. The aim of this review is to provide an overview of the novel discoveries on IFN-I signaling in pediatric-onset SLE.</p><p><strong>Data sources: </strong>A literature search was conducted in the PubMed database using the following keywords: \"pediatric systemic lupus erythematosus\" and \"type I interferon\".</p><p><strong>Results: </strong>IFN-I signaling is increased in pediatric SLE, largely due to the presence of plasmacytoid dendritic cells and pathways such as cyclic GMP-AMP synthase-stimulator of interferon genes-TANK-binding kinase 1 and Toll-like receptor (TLR)4/TLR9. Neutrophil extracellular traps and oxidative DNA damage further stimulate IFN-I production. Genetic variants in IFN-I-related genes, such as IFN-regulatory factor 5 and tyrosine kinase 2, are linked to SLE susceptibility in pediatric patients. In addition, type I interferonopathies, characterized by sustained IFN-I activation, can mimic SLE symptoms and are thus important to distinguish. Studies on interferonopathies also contribute to exploring the pathogenesis of SLE. Measuring IFN-I activation is crucial for SLE diagnosis and stratification. Both IFN-stimulated gene expression and serum IFN-α2 levels are common indicators. Flow cytometry markers such as CD169 and galectin-9 are promising alternatives. Anti-IFN therapies, such as sifalimumab and anifrolumab, show promise in adult patients with SLE, but their efficacy in pediatric patients requires further investigation. Janus kinase inhibitors are another treatment option for severe pediatric SLE patients.</p><p><strong>Conclusions: </strong>This review presents an overview of the IFN-I pathway in pediatric SLE. Understanding the intricate relationship between IFN-I and pediatric SLE may help to identify potential diagnostic markers and targeted therapies, paving the way for improved patient care and outcomes.</p>","PeriodicalId":23883,"journal":{"name":"World Journal of Pediatrics","volume":" ","pages":"653-668"},"PeriodicalIF":6.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11269505/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12519-024-00811-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The role of type I interferon (IFN-I) signaling in systemic lupus erythematosus (SLE) has been well established. However, unanswered questions remain regarding the applicability of these findings to pediatric-onset SLE. The aim of this review is to provide an overview of the novel discoveries on IFN-I signaling in pediatric-onset SLE.

Data sources: A literature search was conducted in the PubMed database using the following keywords: "pediatric systemic lupus erythematosus" and "type I interferon".

Results: IFN-I signaling is increased in pediatric SLE, largely due to the presence of plasmacytoid dendritic cells and pathways such as cyclic GMP-AMP synthase-stimulator of interferon genes-TANK-binding kinase 1 and Toll-like receptor (TLR)4/TLR9. Neutrophil extracellular traps and oxidative DNA damage further stimulate IFN-I production. Genetic variants in IFN-I-related genes, such as IFN-regulatory factor 5 and tyrosine kinase 2, are linked to SLE susceptibility in pediatric patients. In addition, type I interferonopathies, characterized by sustained IFN-I activation, can mimic SLE symptoms and are thus important to distinguish. Studies on interferonopathies also contribute to exploring the pathogenesis of SLE. Measuring IFN-I activation is crucial for SLE diagnosis and stratification. Both IFN-stimulated gene expression and serum IFN-α2 levels are common indicators. Flow cytometry markers such as CD169 and galectin-9 are promising alternatives. Anti-IFN therapies, such as sifalimumab and anifrolumab, show promise in adult patients with SLE, but their efficacy in pediatric patients requires further investigation. Janus kinase inhibitors are another treatment option for severe pediatric SLE patients.

Conclusions: This review presents an overview of the IFN-I pathway in pediatric SLE. Understanding the intricate relationship between IFN-I and pediatric SLE may help to identify potential diagnostic markers and targeted therapies, paving the way for improved patient care and outcomes.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
小儿系统性红斑狼疮中的 I 型干扰素途径。
背景:I型干扰素(IFN-I)信号传导在系统性红斑狼疮(SLE)中的作用已得到公认。然而,关于这些研究结果是否适用于儿童发病的系统性红斑狼疮,仍有许多未解之谜。本综述旨在概述有关儿科发病型系统性红斑狼疮中 IFN-I 信号传导的新发现:在PubMed数据库中使用以下关键词进行了文献检索:数据来源:在PubMed数据库中使用以下关键词进行文献检索:"小儿系统性红斑狼疮 "和 "I型干扰素":IFN-I信号在小儿系统性红斑狼疮中增加,这主要是由于浆细胞树突状细胞的存在以及环GMP-AMP合成酶-干扰素基因刺激器-TANK结合激酶1和Toll样受体(TLR)4/TLR9等通路的存在。中性粒细胞胞外陷阱和氧化 DNA 损伤会进一步刺激 IFN-I 的产生。IFN-I 相关基因(如 IFN 调节因子 5 和酪氨酸激酶 2)的基因变异与儿童患者的系统性红斑狼疮易感性有关。此外,以 IFN-I 持续激活为特征的 I 型干扰素病可以模拟系统性红斑狼疮的症状,因此必须加以区分。对干扰素病的研究也有助于探索系统性红斑狼疮的发病机制。测量 IFN-I 的激活对于系统性红斑狼疮的诊断和分层至关重要。IFN刺激基因表达和血清IFN-α2水平都是常见的指标。CD169和galectin-9等流式细胞术标记物是很有前途的替代指标。西法木单抗(sifalimumab)和阿尼单抗(anifrolumab)等抗IFN疗法在成年系统性红斑狼疮患者中显示出良好的疗效,但它们在儿童患者中的疗效还需要进一步研究。Janus 激酶抑制剂是严重儿童系统性红斑狼疮患者的另一种治疗选择:本综述概述了小儿系统性红斑狼疮的 IFN-I 通路。了解 IFN-I 与小儿系统性红斑狼疮之间错综复杂的关系有助于确定潜在的诊断标志物和靶向疗法,为改善患者护理和预后铺平道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
World Journal of Pediatrics
World Journal of Pediatrics 医学-小儿科
CiteScore
10.50
自引率
1.10%
发文量
592
审稿时长
2.5 months
期刊介绍: The World Journal of Pediatrics, a monthly publication, is dedicated to disseminating peer-reviewed original papers, reviews, and special reports focusing on clinical practice and research in pediatrics. We welcome contributions from pediatricians worldwide on new developments across all areas of pediatrics, including pediatric surgery, preventive healthcare, pharmacology, stomatology, and biomedicine. The journal also covers basic sciences and experimental work, serving as a comprehensive academic platform for the international exchange of medical findings.
期刊最新文献
Could physical activity promote indicators of physical and psychological health among children and adolescents? An umbrella review of meta-analyses of randomized controlled trials. Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System. Global burden of heart failure in children and adolescents from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019. Sex dimorphic associations of Prader-Willi imprinted gene expressions in umbilical cord with prenatal and postnatal growth in healthy infants. Accelerometry-assessed sleep clusters and obesity in adolescents and young adults: a longitudinal analysis in GINIplus/LISA birth cohorts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1